MYLS22

Names

[ Name ]:
MYLS22

[Synonym ]:
MFCD01062681

Biological Activity

[Description]:

MYLS22 is a first-in-class and selective optic atrophy 1 (OPA1) inhibitor. MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression[1].

[Related Catalog]:

Research Areas >> Cancer

Research Areas >> Cardiovascular Disease

Signaling Pathways >> Others >> Others

[Target]

OPA1[1]

[In Vivo]

MYLS22 (10 mg/kg/die; peritumoral injection; every 2 days for 14 days) causes the tumor growth curtailed mice[1]. Animal Model: 6-week-old C57BL6/J mice with B16F10 melanomas[1] Dosage: 10 mg/kg/die Administration: Peritumoral injection; every 2 days for 14 days Result: Caused the tumor growth curtailed.

[References]

[1]. Stéphanie Herkenne, et al. Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1. Cell Metab. 2020 May 5;31(5):987-1003.e8.

Chemical & Physical Properties

[ Molecular Formula ]:
C₂₄H₂₁N₅O₂S

[ Molecular Weight ]:
443.52

Safety Information

[ Hazard Codes ]:
Xi

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.